Biogen’s Tecfidera Resilience Reflects ‘Inefficiencies In US System’
Payment Quirk Also Means Doctors Currently ‘May Prefer Vumerity’
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.
